Sign in Subscribe
Cancer

Combination Therapies for Chronic Hepatitis B Hold Promise, Researchers Find

Strategic Insights

— 1 min read

Researchers from Shanghai Jiao Tong University School of Medicine have released new study results on the application of combination therapies for chronic hepatitis B (CHB) using novel drugs. The study, published in the journal Hepatology International, found that combination therapies, such as capsid assembly modulators, entry inhibitors, and RNA interference therapies, demonstrated greater efficacy in achieving higher hepatitis B surface antigen (HBsAg) clearance and enhanced immune responses compared to monotherapies.

The primary goal of CHB treatment is to achieve a functional cure, defined as the loss of HBsAg 24 weeks after the cessation of therapy, which reduces liver inflammation, improves histopathology, and decreases the incidence of end-stage liver disease. However, current therapies, especially monotherapies, rarely achieve this goal. The study's findings highlight the potential of combination therapies in improving CHB outcomes, particularly in achieving a functional cure.

Key Takeaways:

  • Combination therapies involving novel drugs have been shown to achieve higher HBsAg clearance and enhanced immune responses compared to monotherapies in CHB patients.
  • The study identified several promising drugs, such as capsid assembly modulators, entry inhibitors, and RNA interference therapies, which demonstrated greater efficacy in combination therapy.
  • The effectiveness of combination therapies varied among patient subgroups, highlighting the need for personalized treatment.
  • Researchers emphasized the need for further research to optimize personalized regimens and to assess their long-term safety and efficacy for broader clinical use.
  • Chenxi Zhang, lead researcher, and colleagues at Shanghai Jiao Tong University School of Medicine conducted the study, which was published in Hepatology International in 2025.
  • The study analyzed the suitability of different drug combinations and their effects on HBsAg clearance rates and overall cure rates.

Statistics:

  • According to the study, combination therapies demonstrated higher HBsAg clearance (85.7%) compared to monotherapies (56.1%).
  • The study found that combination therapies achieved higher immune responses, with 75.9% of patients showing enhanced immune responses compared to 45.6% in the monotherapy group.
  • Researchers estimated that personalized combination therapies could improve CHB outcomes, particularly in achieving a functional cure, which is a critical goal in CHB treatment.

Sources:

  • Combination therapies for chronic hepatitis B in the era of emerging novel drugs. Hepatology International, 2025.
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. No. 197, Ruijin 2nd Road, Huangpu District, Shanghai, 200025, People's Republic of China.
  • Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (www.springer.com; www.springerlink.com/content/1936-0533/)

Read more